Our results suggest that the activity of FANCI is needed for a subset of prostate cancer cells to survive under DNA damage-inducing chemotherapy, and FANCI depletion leads to the downregulation of multiple FA pathway genes and thus most likely to the inactivation of the FA pathway in prostate cancer. The gene discussed is FANCI; the disease is prostate carcinoma.